236 related articles for article (PubMed ID: 37542594)
1. Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
Lee A
Target Oncol; 2023 Sep; 18(5):793-800. PubMed ID: 37542594
[TBL] [Abstract][Full Text] [Related]
2. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
[TBL] [Abstract][Full Text] [Related]
3. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
Wenzel M; Hoeh B; Chun FKH; Mandel P
Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Shore ND; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Tombal B; Nordquist L; Cookson M; Verholen F; Jhaveri J; Srinivasan S; Smith MR
Oncologist; 2024 Mar; 29(3):235-243. PubMed ID: 37812679
[TBL] [Abstract][Full Text] [Related]
5. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
[TBL] [Abstract][Full Text] [Related]
6. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
[TBL] [Abstract][Full Text] [Related]
7. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T
Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807
[TBL] [Abstract][Full Text] [Related]
8. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
[TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
10. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
Kafka M; Giannini G; Artamonova N; Neuwirt H; Ofner H; Kramer G; Bauernhofer T; Luger F; Höfner T; Loidl W; Griessner H; Lusuardi L; Bergmaier A; Berger A; Winder T; Weiss S; Bauinger S; Krause S; Drerup M; Heinrich E; Schneider M; Madersbacher S; Vallet S; Stoiber F; Laimer S; Hruby S; Schachtner G; Nagele U; Lenart S; Ponholzer A; Pfuner J; Wiesinger C; Kamhuber C; Müldür E; Bektic J; Horninger W; Heidegger I
Clin Genitourin Cancer; 2024 Apr; 22(2):458-466.e1. PubMed ID: 38267304
[TBL] [Abstract][Full Text] [Related]
11. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
[TBL] [Abstract][Full Text] [Related]
12. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
13. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford ED; Kopyltsov E; Park CH; Alekseev B; Montesa-Pino Á; Ye D; Parnis F; Cruz F; Tammela TLJ; Suzuki H; Utriainen T; Fu C; Uemura M; Méndez-Vidal MJ; Maughan BL; Joensuu H; Thiele S; Li R; Kuss I; Tombal B;
N Engl J Med; 2022 Mar; 386(12):1132-1142. PubMed ID: 35179323
[TBL] [Abstract][Full Text] [Related]
14. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M; Tombal B; Saad F; Fizazi K; Sternberg CN; Crawford ED; Shore N; Kopyltsov E; Kalebasty AR; Bögemann M; Ye D; Cruz F; Suzuki H; Kapur S; Srinivasan S; Verholen F; Kuss I; Joensuu H; Smith MR
J Clin Oncol; 2023 Jul; 41(20):3595-3607. PubMed ID: 36795843
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
[TBL] [Abstract][Full Text] [Related]
16. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
Menges D; Yebyo HG; Sivec-Muniz S; Haile SR; Barbier MC; Tomonaga Y; Schwenkglenks M; Puhan MA
Eur Urol Oncol; 2022 Dec; 5(6):605-616. PubMed ID: 35599144
[TBL] [Abstract][Full Text] [Related]
17. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
18. Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.
Wala J; Nguyen P; Pomerantz M
J Clin Oncol; 2023 Jul; 41(20):3584-3590. PubMed ID: 37267579
[No Abstract] [Full Text] [Related]
19. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
Fiorica F; Buttigliero C; Grigolato D; Muraro M; Turco F; Munoz F; Tucci M
Curr Oncol; 2022 Dec; 29(12):9511-9524. PubMed ID: 36547161
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Azad AA; Armstrong AJ; Alcaraz A; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alekseev B; Iguchi T; Shore ND; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):274-282. PubMed ID: 34420037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
